Publisher: Adis International
ISSN: 1537-1328
Source: Pharmaceutical Innovation, Vol.11, Iss.2, 2002-03, pp. : 30-31
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
IV immunoglobulin (IVIG) is a valid maintenance therapy option for myasthenia gravis
Inpharma, Vol. 1, Iss. 1299, 2001-01 ,pp. :
Immunomodulatory treatment for myasthenia gravis
Inpharma, Vol. 1, Iss. 1283, 2001-01 ,pp. :
Mouse Models of Myasthenia Gravis
Current Pharmaceutical Design, Vol. 21, Iss. 18, 2015-06 ,pp. :
Diagnosis and Management of Autoimmune Myasthenia Gravis
Clinical Drug Investigation, Vol. 31, Iss. 1, 2011-01 ,pp. :
Fluoroquinolones linked with myasthenia gravis exacerbation
Reactions Weekly, Vol. 1, Iss. 1370, 2011-01 ,pp. :